Q4 25 EPS
$0.20
BEAT +0.00%
Est. $0.20
Q4 25 Revenue
$139.2M
MISS 0.46%
Est. $139.8M
vs S&P Since Q4 25
-51.3%
TRAILING MARKET
ADMA -44.9% vs S&P +6.4%
Full Year 2025 Results
FY 25 EPS
$0.60
FY 25 Revenue
$510.2M
Market Reaction
Did ADMA Beat Earnings? Q4 2025 Results
ADMA Biologics closed out 2025 on strong footing, reporting fourth-quarter revenue of $139.16 million, an 18% year-over-year increase, with earnings per share of $0.20 meeting analyst expectations. The primary engine behind the quarter was ASCENIV, t… Read more ADMA Biologics closed out 2025 on strong footing, reporting fourth-quarter revenue of $139.16 million, an 18% year-over-year increase, with earnings per share of $0.20 meeting analyst expectations. The primary engine behind the quarter was ASCENIV, the company's high-margin immunoglobulin therapy, which drove full-year revenue of $510.17 million, up 20% from the prior year, while contributing to gross margin expansion that reached 63.8% in Q4 versus 53.9% a year earlier. That margin improvement reflects the successful integration of yield-enhanced production processes, with 2026 expected to represent the first full year of that output running through commercial operations. Adjusted EBITDA surged 52% in the quarter to $73.59 million, underscoring the operating leverage building in the business. Looking ahead, management reiterated guidance for revenue exceeding $635.00 million in 2026 and a path toward $1.10 billion by 2029, confidence the company reinforced by launching a $200.00 million share repurchase initiative, including a $125.00 million accelerated agreement with JPMorgan.
Key Takeaways
- • Record ASCENIV demand with 51% year-over-year revenue growth driven by strong prescriber adoption and broad payer access
- • Yield-enhanced production fully integrated into commercial operations driving gross margin expansion to 57.4% for FY 2025 from 51.5% in FY 2024
- • Q4 2025 gross margins reached 63.8%, up from 53.9% in Q4 2024
- • Continued mix shift toward higher-margin IVIG products, particularly ASCENIV
- • Real-world data publications reinforcing ASCENIV differentiation and adoption
ADMA YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
ADMA Revenue by Segment
With YoY comparisons, source: SEC Filings
“2025 marked a year of disciplined execution, record performance and meaningful strategic progress for ADMA, and we are entering 2026 with significant momentum. Record ASCENIV demand, strong prescriber adoption and broad payer access underscores the strength and durability of our commercial platform and the continued expansion of the IVIG end market. With ASCENIV still forecasted to be early in its penetration curve and driven by our vertically integrated manufacturing model and enhanced plasma supply visibility, we believe ADMA is well positioned to deliver outsized revenue growth, higher margins and increasing earnings power in the years ahead.”
— Adam Grossman, Q4 2025 Earnings Press Release
ADMA Earnings Trends
ADMA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ADMA EPS Trend
Earnings per share: estimate vs actual
ADMA Revenue Trend
Quarterly revenue: estimate vs actual
ADMA Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.20 | $0.19 | -5.00% | $114.5M | -18.20% |
| Q4 25 BEAT FY | $0.20 | $0.20 | +0.00% | $139.2M | -0.46% |
| FY Full Year | — | $0.60 | — | $510.2M | — |
| Q3 25 MISS | $0.16 | $0.15 | -3.23% | $134.2M | +2.83% |
| Q2 25 BEAT | $0.14 | $0.14 | +3.70% | $122.0M | +0.18% |
| Q1 25 MISS | $0.13 | $0.11 | -15.38% | $114.8M | -1.37% |